Search

Your search keyword '"Ray, Neelanjana"' showing total 16 results

Search Constraints

Start Over You searched for: Author "Ray, Neelanjana" Remove constraint Author: "Ray, Neelanjana" Database Academic Search Index Remove constraint Database: Academic Search Index
16 results on '"Ray, Neelanjana"'

Search Results

1. Kersten T. Hall, Insulin—the crooked timber: a history from thick brown muck to wall street gold, Oxford: Oxford university press, 2021.

2. The Second-Generation Maturation Inhibitor GSK3532795 Maintains Potent Activity Toward HIV Protease Inhibitor-Resistant Clinical Isolates.

3. Prediction of Virological Response and Assessment of Resistance Emergence to the HIV-1 Attachment Inhibitor BMS-626529 During 8-Day Monotherapy With Its Prodrug BMS-663068.

4. Study of Andes virus entry and neutralization using a pseudovirion system

5. Inefficient entry of vicriviroc-resistant HIV-1 via the inhibitor-CCR5 complex at low cell surface CCR5 densities

6. HR-2 Mutations in Human Immunodeficiency Virus Type 1 gp41 Restore Fusion Kinetics Delayed by HR-1 Mutations That Cause Clinical Resistance to Enfuvirtide.

7. Cyclooxygenase-1 and -2 Are Required for Production of Infectious Pseudorabies Virus.

8. Transcriptional Response of a Common Permissive Cell Type to Infection by Two Diverse Alphaherpesviruses.

9. Resistance profile of the HIV-1 maturation inhibitor GSK3532795 in vitro and in a clinical study.

10. Clinical Resistance to Enfuvirtide Does Not Affect Susceptibility of Human Immunodeficiency Virus Type 1 to Other Classes of Entry Inhibitors.

11. N-terminal substitutions in HIV-1 gp41 reduce the expression of non-trimeric envelope glycoproteins on the virus

12. Antiviral Activity, Safety, and Exposure–Response Relationships of GSK3532795, a Second-Generation Human Immunodeficiency Virus Type 1 Maturation Inhibitor, Administered as Monotherapy or in Combination With Atazanavir With or Without Ritonavir in a Phase 2a Randomized, Dose-Ranging, Controlled Trial (AI468002).

13. Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral Therapy.

14. Genotypic correlates of susceptibility to HIV-1 attachment inhibitor BMS-626529, the active agent of the prodrug BMS-663068.

15. Pharmacodynamics, Safety, and Pharmacokinetics of BMS-663068, an Oral HIV-1 Attachment Inhibitor in HIV-1–Infected Subjects.

16. Enhanced Phosphatase Activity Attenuates α-Synucleinopathy in a Mouse Model.

Catalog

Books, media, physical & digital resources